ECF chemotherapy for liver metastases due to castration-resistant prostate cancer

Canadian Urological Association Journal

Volumn 8, Issue 9-10, 2014, Pages 353-357

  Gupta, Shruti ^a   Potvin, Kylea ^a,b   Ernst, D Scott ^a,b   Whiston, Frances ^c   Winquist, Eric ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919919981     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.2029     Document Type: Article

References (23)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON; Canadian Cancer Society; 2011:16-7.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. http://dx.doi.org/10.1038/35094009
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. http://dx.doi.org/10.1056/NEJMoa040720
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. http://dx.doi.org/10.1056/NEJMoa041318
5. Armstrong AJ, Garrett-Mayer E, de Wit R, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010;16:203-11. http://dx.doi.org/10.1158/1078-0432.CCR-09-2514
6. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
7. Chao D, von Schlippe M, Harland SJ. A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: An active new regimen. Eur J Cancer 1997;33:1230-3. http://dx.doi.org/10.1016/S0959-8049(97)00097-X
8. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. http://dx.doi.org/10.1016/S1053-4296(03)00031-6
9. Birtle AJ, Newby JC, Harland SJ. Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer 2004;91:1472-6.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. http://dx.doi.org/10.1016/j.ejca.2008.10.026
11. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59. http://dx.doi.org/10.1200/JCO.2007.12.4487
12. Pezaro CJ, Omlin A, Lorente D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65:270-3. http://dx.doi.org/10.1016/j.eururo.2013.10.055
13. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castrationresistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30:1534-40. http://dx.doi.org/10.1200/JCO.2011.39.4767
14. McGovern UB, Harland SJ. Use of epirubicin, carboplatin, and 5-fluorouracil (ECarbF) as a second-line treatment in metastatic castration-resistant prostate cancer. J Clin Oncol 2011:29 (suppl 7; abstr 173).
15. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46. http://dx.doi.org/10.1056/NEJMoa073149
16. Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109:477-86. http://dx.doi.org/10.1002/cncr.22439
17. Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel/carboplatin-based chemotherapy as first-and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 2008;101:308-12. http://dx.doi.org/10.1111/j.1464-410X.2007.07331.x
18. Fléchon A, Pouessel D, Ferlay C, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22:2476-81. http://dx.doi.org/10.1093/annonc/mdr004
19. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147-54. http://dx.doi.org/10.1016/S0140-6736(10)61389-X
20. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. http://dx.doi.org/10.1056/NEJMoa1014618
21. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97. http://dx.doi.org/10.1056/NEJMoa1207506
22. Goodman OB Jr, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013:1-6.
23. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet Oncol 2013;14:760-8. http://dx.doi.org/10.1016/S1470-2045(13)70184-0